SIGA Technologies, Inc. (SIGA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$3.29+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SIGA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On August 6, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Annual board election with no specific departures or appointments mentioned.
Results of Operations and Financial Condition. On May 7, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three months ended March 31, 2026. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Other Events. On March 26, 2026, SIGA Technologies, Inc. announced that it declared a special, one-time cash dividend of $0.60 per share of common stock. The dividend is payable on April 23, 2026 to holders of record on April 7, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGA TECHNOLOGIES, INC. By: /s/ Daniel J. Luckshire Nam…
Results of Operations and Financial Condition. On March 10, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and twelve months ended December 31, 2025. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange A…
Results of Operations and Financial Condition. On November 6, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…
Results of Operations and Financial Condition. On August 5, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Results of Operations and Financial Condition. On May 8, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three months ended March 31, 2025. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Other Events. On April 8, 2025, SIGA Technologies, Inc. announced that it declared a special, one-time cash dividend of $0.60 per share of common stock. The dividend is payable on May 15, 2025 to holders of record on April 29, 2025. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGA TECHNOLOGIES, INC. By: /s/ Daniel J. Luckshire Name:…
Director — General John M. “Jack” Keane (Ret.): Gen. Keane was appointed as a new director of the Company.
Results of Operations and Financial Condition. On March 11, 2025, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and twelve months ended December 31, 2024. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange A…
Results of Operations and Financial Condition. On November 7, 2024, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2024. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…
Amendments to employment agreements for CFO and Chief Scientific Officer, adjusting incentive compensation opportunities.
Executive Vice President and Chief Medical Officer — Dr. Jay Varma: Dr. Jay Varma was terminated from his position as Executive Vice President and Chief Medical Officer.
Executive Vice President and Chief Medical Officer, Director — Dr. Jay K. Varma: Dr. Jay K. Varma began an indefinite leave of absence from his positions.
Results of Operations and Financial Condition. On August 1, 2024, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2024. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Other Events. On July 19, 2024, SIGA Technologies, Inc. issued a press release (the “Press Release”) entitled “SIGA Announces U.S. Government Procurement Order of Approximately $113 Million for Oral TPOXX®.” The full text of the Press Release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On May 7, 2024, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Entry into a Material Definitive Agreement On March 27, 2024, SIGA Technologies, Inc. (the “Company”) and Meridian Medical Technologies, LLC (“Meridian”) entered into an amendment (the “Amendment”) to the Promotion Agreement, dated as of May 31, 2019, by and between the Company and Meridian, as amended (the “Promotion Agreement”). The changes to the Promotion Agreement contemplated by the Amendment are effective as of June 1, 2024. Under the terms of the Promotion Agreement, as amended (the “…
Results of Operations and Financial Condition. On March 12, 2024, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and twelve months ended December 31, 2023. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange A…
CEO — Diem Nguyen, Ph.D., MBA: Dr. Diem Nguyen was appointed as the new CEO and a board member, bringing significant industry experience.
Chief Executive Officer — Phillip Louis Gomez, III: Dr. Gomez will continue to serve as CEO until a successor is appointed or March 31, 2024.
Results of Operations and Financial Condition. On November 7, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and nine months ended September 30, 2023. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange…
Executive Vice President and Chief Medical Officer — Dr. Jay K. Varma: Dr. Jay K. Varma was appointed as Executive Vice President and Chief Medical Officer.
Results of Operations and Financial Condition. On August 8, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and six months ended June 30, 2023. Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.